The Hygiology Post is presenting information about a company that seems to have much potential to help many people. 2012 may be a pivotal year in determining how helpful the patented technologies may actually be for people.
Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; obtained on 9-15-12). As a matter of disclosure : The author continues to be a current shareholder in the company.
The Senesco Technologies web site ( https://www.senesco.com/newsitem.php?id=260; obtained on 9-15-12) has posted relevant information about its research. Here is an excerpt:
Senesco Announces First Dose of SNS01-T in Cohort 2 of Phase 1b/2a Study in Multiple Myeloma Trial
BRIDGEWATER, N.J. (September 13th, 2012) – Senesco Technologies, Inc. (‘Senesco’ or the ‘Company’) (NYSE MKT: SNT) reported today that the first patient has been enrolled and dosing has been initiated in cohort 2 of its clinical trial with SNS01-T in multiple myeloma. SNS01-T was well tolerated and met the criteria for Stable Disease in 2 of the 3 evaluable patients that comprised cohort 1.
‘We were very pleased that the first group, infused with the lowest dose of SNS01-T provided encouraging results including two patients with stable disease of which one patient remained stable at 4 weeks and progressed at 8 weeks after the end of the dosing period,’ stated Leslie J. Browne, Ph.D., President and CEO of Senesco. ‘Now that cohort 2 is underway and there are three clinical sites recruiting patients we hope to be able to disclose results on the four-fold higher dose of approximately 4 mg per patient around the end of 2012.’ ”
The Hygiology Post welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2012 The Hygiology Post